Erasca reports early data on ERAS-007 combos: 40% response in BRAFm CRC; stops palbociclib combo in KRASm tumors

Erasca, Inc.

ERAS-007 + encorafenib + cetuximab in BRAF V600E CRC: 40% response (2/5) at 100mg BID-QW, 29% overall across doses.
Combination generally well-tolerated with mostly low-grade AEs; one DLT (Grade 3 macular edema) at highest dose.
ERAS-007 + palbociclib showed no clinical activity in KRAS/NRAS mutant CRC and KRASm PDAC; company will not pursue combo.
Additional Phase 1b HERKULES-3 data in BRAF-mutated CRC expected between H2 2023 and H1 2024.
PK exposures of ERAS-007, encorafenib, cetuximab comparable to monotherapy, no significant drug-drug interactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.